SCHEMBL9922282

SCHEMBL9922282

CNc1ccc2c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(C)s4)cc3F)cc(C)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.43
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CA12 O43570 6/20 0.37
CA9 Q16790 6/20 0.37
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36
CA1 P00915 3/20 0.34
CA2 P00918 2/20 0.34
KIT P10721 1/20 0.34
SCN2B O60939 1/20 0.33
SCN1B Q07699 1/20 0.33
SCN5A Q14524 1/20 0.33
SCN9A Q15858 1/20 0.33
USP2 O75604 1/20 0.33
TP53 P04637 2/20 0.32
IDH1 O75874 1/20 0.32
MAPT P10636 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12177065 0.92 P2RY12 (0.53) P2RY12MEN1KMT2ACA12CA9
SCHEMBL9922284 0.92 P2RY12 (0.42) P2RY12MEN1KMT2ACA12CA9
SCHEMBL13638554 0.91 P2RY12 (0.41) P2RY12MEN1KMT2ACA12CA9
SCHEMBL9922581 0.91 P2RY12 (0.41) P2RY12MEN1KMT2ACA12CA9
SCHEMBL9922586 0.90 P2RY12 (0.40) P2RY12MEN1KMT2ACA12CA9
SCHEMBL9922630 0.90 P2RY12 (0.42) P2RY12MEN1KMT2ACA12CA9
SCHEMBL13182775 0.89 P2RY12 (0.40) P2RY12MEN1KMT2ACA12CA9
SCHEMBL9922293 0.89 P2RY12 (0.40) P2RY12MEN1KMT2ACA12CA9
SCHEMBL13182776 0.88 P2RY12 (0.39) P2RY12MEN1KMT2ACA12CA9
SCHEMBL13638566 0.88 MEN1 (0.45) P2RY12MEN1KMT2ACA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-20080194597-A1 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PORTOLA PHARMACEUTICALS, INC. (US) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194597-A1 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PIGS, GP6, ASGR1 P2RY12 89/4885MEN1 4750/4885KMT2A 3608/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 18/4885MEN1 4499/4885KMT2A 3023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.